Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study

The incidence of bone metastases in non-small cell lung cancer (NSCLC) patients is about 30-40% and bone-related events can seriously affect quality of life. Immune checkpoint inhibitor (ICI) therapy has become the standard treatment for advanced NSCLC patients. However, the specific efficacy of ICI...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Translational lung cancer research 2022-01, Vol.11 (1), p.87-99
Hauptverfasser:	Qiang, Huiping, Lei, Yuqiong, Shen, Yinchen, Li, Jiaqi, Zhong, Hua, Zhong, Runbo, Zhang, Xueyan, Chang, Qing, Lu, Jiahuan, Feng, Hui, Zhu, Yan, Addeo, Alfredo, Banna, Giuseppe L, Oh, In-Jae, Qian, Jialin, Chu, Tianqing
Format:	Artikel
Sprache:	eng
Schlagworte:	Original
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!